
Episode #33
Episode 33 — Dr. Morteza Rasoulianboroujeni on research into nanomedicine for cancer treatment
On this episode of White Coat Radio, we welcome Dr. Morteza Rasoulianboroujeni, who joined East Tennessee State University Bill Gatton College of Pharmacy as an Assistant Professor of Pharmaceutical Sciences in July 2025. Prior to joining ETSU, he earned his Ph.D. in Pharmaceutical Sciences and completed postdoctoral training at the University of Wisconsin–Madison. His research focuses on developing drug delivery systems, with particular emphasis on improving the formulation and biodistribution of nanomedicines for cancer treatment. Full transcription: 00;00;09;20 - 00;00;39;10 Morteza Rasoulianboroujeni The very first thing that impressed me with, about ETSU what people and the culture we have here. And I got to join ETSU. And here I am. 00;00;39;13 - 00;01;02;20 Michele Williams Welcome to White Coat Radio, a podcast from East Tennessee State University. Bill Gatton College of Pharmacy in Johnson City, Tennessee. Each episode we cover a wide range of topics about the pharmacy school experience, from study tips to deep dives with faculty and student pharmacists. I'm one of your host Dr. Michelle Williams, assistant professor and director of academic success. 00;01;02;22 - 00;01;29;04 Stephen Woodward And I'm Stephen Woodward, marketing and communications manager. Today we welcome Dr. Morteza Rasoulianboroujeni, who joined Gatton as an assistant professor in pharmaceutical sciences in July of 2025. Prior to ETSU, he earned his PhD in pharmaceutical sciences and completed post-doctoral training at the University of Wisconsin-Madison. His research focuses on the development of drug delivery systems, with particular emphasis on improving formulation and bio distribution of nanomedicine for cancer treatment. 00;01;29;06 - 00;01;35;05 Stephen Woodward Dr. Rasoulian welcome to White Coat Radio. We're so glad you're here. And would you mind just introduce yourself? 00;01;35;08 - 00;01;55;00 Morteza Rasoulianboroujeni Oh, thank you so much. I'm very excited and very happy to be here. Thanks for inviting me. My name is. My first name is Morteza. My last name is Rasoulian. People here in the school may see my the long version of my last name, which is indeed. I'm going to take this opportunity to explain why my last name is so. 00;01;55;02 - 00;01;57;21 Michele Williams Thank you for that, by the way. 00;01;57;23 - 00;02;20;11 Morteza Rasoulianboroujeni So my my last name is Rasoulian. So students can feel free to call me with that last name. The second part of what you see in my last name is actually the city I was born in. So there should be space between the two. But, because it might be confused with a middle name versus a last name, if someone puts a space in between the two. 00;02;20;14 - 00;02;47;01 Morteza Rasoulianboroujeni That's why we try to kind of keep the two words together. So Boroujeni is my last name and which is the city I was born in. I got my PhD at University of Wisconsin-Madison and joined Gatton College of Pharmacy in July 2025 as an assistant professor. And I'm very glad to be here. I'll be happy to kind of talk about more more about my background that sounds great. 00;02;47;03 - 00;02;57;24 Michele Williams That does sound great. And we're really, really happy to have you here. And, tell us a little bit about your the career path that led you to Gatton. 00;02;57;26 - 00;03;26;02 Morteza Rasoulianboroujeni Sure. That's a very good question, because I sometimes think about kind of how I got here and kind of, like, chose this, career and becoming a faculty. It's a long story, but if I'm going to start from the very beginning, I was always very interested in working in healthcare, things like including biotech, but I was I was also very, very good at math. 00;03;26;05 - 00;04;01;18 Morteza Rasoulianboroujeni So when I wanted to start my undergrad program, I was always thinking I wanted to be an engineer because I've, like, been good at math. But I really loved biology and the application of all those kind of things in biology. So I decided to go for a biomedical engineering program. So that was my undergrad background. And then later, in my kind of experience in at the university, I learned more about drug delivery, which is, one of the fields that biomedical engineers work on and also pharmaceutical scientists. 00;04;01;21 - 00;04;46;29 Morteza Rasoulianboroujeni And I kind of like I can say, I fell in love with that, with that field to kind of work on it. And I joined several labs to, to kind of work on different aspects of this. I've worked for Marquette University School of Dentistry for a while before I start my PhD, and there was a biomaterials lab over there that I work and I learned that I want to take my research experience to the next level and start a research based career, which for me in, in that time was either becoming a faculty and have my own research program, or joining a biotech company, like a pharmaceutical company. 00;04;47;02 - 00;05;13;23 Morteza Rasoulianboroujeni And for both, a PhD could be the route to kind of get there. So I started applying for it for graduate schools. I joined the University of Wisconsin, and I did my PhD there. It might be very interesting, if you know that before the end of my PhD, like I was, I was I was applying and getting interviewed by pharmaceutical companies, like Merck and Johnson and Johnson. 00;05;13;26 - 00;05;50;26 Morteza Rasoulianboroujeni But during the interviews and doing more research, I started to think that is it. What I'm going to do long term, kind of. It was it was very attractive for me because they deal with the end product that at the next step goes to market or, into the clinic and kind of helps patients. But at the same time, you know, as you get to that level of quality control, CMC manufacturing and all those kind of things, you can have less of innovative research and initiating new projects and kind of have that freedom to work on whatever you excites you. 00;05;51;01 - 00;06;19;15 Morteza Rasoulianboroujeni And it more like you have to stick to very, serious and well established standards. Right? So then I was like, okay, maybe I'm interested in a research, but maybe more like early stage innovative kind of research. And that's when I decided to join a startup company. So during the last year of my PhD and early days are postdocs I worked with a startup company in San Francisco for a while. 00;06;19;15 - 00;06;49;26 Morteza Rasoulianboroujeni I was between like flying between Madison and San Francisco. Oh my. For a long time. And then over there. It was exciting to do this kind of research, because that was at at the interface of kind of introducing a new technology and commercialize that. Right? I'm still very interested in that. But what I also learned is that I like to stand here, but I also want to be able to initiate new ideas to feed into this pipeline. 00;06;50;03 - 00;07;17;14 Morteza Rasoulianboroujeni So after finishing my postdoc, I learned that a faculty position in, School of Pharmacy can help me do that. That's why I was like, I'm going to apply for faculty positions while also keeping in touch with the startup companies in order to translate my research to, to, to a startup companies and later as a product. So applying for, pharmacy schools to become a faculty. 00;07;17;17 - 00;07;34;21 Morteza Rasoulianboroujeni I got familiar with Etsu. I interviewed here the very first thing that impressed me with, about Etsu, where people and the culture we have here. And I got to join Etsu, and here I am. 00;07;34;24 - 00;07;39;14 Stephen Woodward So that's great. We hear that so much about the culture. And the people here are definitely people first. 00;07;39;17 - 00;07;52;26 Michele Williams Yeah, and you fit right in. Yeah, too. Thank you. Yeah, I can remember when when you came for your interview. We we, either went out to once at breakfast or or lunch or dinner, I can't remember. 00;07;52;26 - 00;07;56;08 Morteza Rasoulianboroujeni I think it was. Yeah, I think it was dinner. 00;07;56;10 - 00;08;00;17 Michele Williams I think I remember thinking that you would be a good fit. 00;08;00;20 - 00;08;30;29 Morteza Rasoulianboroujeni Yeah. Thank you. Yeah, yeah, it was great when when I visited here, like, Etsu had all that research infrastructure that I had. I heard about their plans to further develop this. Yeah. I loved the support of the leadership for research and the plans they have to kind of develop this further. And I also thought it also gives me the freedom to kind of work at this interface of focusing on my own research, while also working with startup companies to try to transition that. 00;08;30;29 - 00;08;54;00 Morteza Rasoulianboroujeni And actually, right now I work with, the office of, research and sponsor programs. Really, kind of I, I joined their that the trainings and all that resources they have for, for, filing a patent for example, how you can spin out the startup, from the university. You know, Etsu is moving toward that direction. I can contribute to that. 00;08;54;01 - 00;08;55;16 Morteza Rasoulianboroujeni That's awesome. Yeah. 00;08;55;18 - 00;09;04;29 Stephen Woodward Well, I could tell you connected well with the students, too, because it will be in retreat. I mean, out of the gate. You were playing volleyball and everything, and and so it was really nice. Got some good pictures of my day. 00;09;05;00 - 00;09;16;25 Morteza Rasoulianboroujeni Yeah. Thank you for that. They they are the best picture salon has ever taken. Oh yeah. Yeah. No, it was the moments, you know, you thought. 00;09;16;27 - 00;09;22;19 Stephen Woodward Yeah well it's great along those lines. And what classes can students expect to see you school. 00;09;22;21 - 00;09;47;26 Morteza Rasoulianboroujeni For the current semester and all the spring semesters? I'm going to be teaching in pharmacology to, and I'm going to be covering the oncology part like oncology drugs, because that's also part of my research. We can talk about it more. But yeah, I focus on cancer and treating cancer for my research. And I'm going to be teaching oncology drugs, for pharmacology too. 00;09;47;28 - 00;10;19;03 Morteza Rasoulianboroujeni In fall semesters I'm going to be teaching pharmacology. One. And in that course I mainly cover antibiotics. And that longer term plan is also for me to cover to, to instruct, PCA. So yeah, right now, I'm joining Doctor Lugo’s classes to kind of see the structure of the course, while also we have another course which is called advanced PCA, and that's for graduate students. 00;10;19;03 - 00;10;29;19 Morteza Rasoulianboroujeni That's a three credit course, which I take care of, one extra credit for graduate students. So right now I'm teaching also in advanced PCA for graduate students. 00;10;29;19 - 00;10;30;21 Michele Williams And PCA is for. 00;10;30;28 - 00;10;34;03 Morteza Rasoulianboroujeni Some other kinetics. Sorry. Yeah I yeah, some of the kinetic. 00;10;34;05 - 00;10;37;17 Michele Williams So there's an advanced PCA strategies that. 00;10;37;17 - 00;10;40;08 Morteza Rasoulianboroujeni Yeah. 00;10;40;10 - 00;10;52;26 Michele Williams So you mentioned your research and I understand that students can work with you definitely research, which is very exciting. So can you give an example of the kind of research that students can do with you? 00;10;52;27 - 00;11;29;07 Morteza Rasoulianboroujeni Sure. I, I'm, I have just begun, establishing my research programs, my research program. I'm going to have two research programs. One of them and and both of them are going to be about nanomedicine. The first one, which is mainly focused on lipid nanoparticles, which are nanoparticles used for in the formulation of Covid vaccines. They are used to package mRNA or other genetic material for gene delivery application, or of course vaccine application. 00;11;29;07 - 00;11;55;09 Morteza Rasoulianboroujeni So these nanoparticles are very complicated to design. And the reason for that is that we do not have enough knowledge about how they structure properties, relationship between what we use in making these nanoparticles and what they can do in the body works. Right. So if, for example, we're going to shoot for a certain application, which is let's say producing insulin for diabetes, right? 00;11;55;09 - 00;12;23;12 Morteza Rasoulianboroujeni So we need to be able to target these nanoparticles with an mRNA for example, in it to their pancreas. Right. So pancreatic tissue but no one knows how you can kind of, decide about formulation components and how you can mix them in order to, kind of control the bio distribution in the body and target them toward pancreatic, pancreatic tissue or any tissue of interest. 00;12;23;15 - 00;12;49;09 Morteza Rasoulianboroujeni But we know that there's a correlation between the two. What I'm trying to do in my research is using artificial intelligence AI to establish this structure. Property relationships, because we can have data for formulation and we can have data for the final response, which is, for example, accumulation in a certain tissue or, entering the cell or expressing a certain protein, whatever it is. 00;12;49;10 - 00;13;18;27 Morteza Rasoulianboroujeni So we're trying to establish AI models for these lipid nanoparticle design and have an AI guided design of lipid nanoparticles. So because this doesn't need that lab work at this point and is more computational, I have already initiated that program. And actually I have some student faculty students already involved in that project. And then the second, like at some point when we use AI to design these lipid nanoparticles, we will try them in real world, like in vet lab. 00;13;18;27 - 00;13;42;01 Morteza Rasoulianboroujeni So we will formulate what I suggest us to formulate. And then we administer them like we inject them to animals to see whether they work the way they're supposed to work, as AI is guiding us in that direction. So that's one of the research programs. And the longer term goal is this the second research program I'm trying to establish, but it needs an extra, some extra time, to get there. 00;13;42;01 - 00;13;57;22 Morteza Rasoulianboroujeni Where we can initiate this project is on cancer and nanomedicine, which we use polymeric nanoparticles to encapsulate chemo drugs and change their pharmacokinetic and bio distribution in order to reduce the side effects and increase the efficacy. 00;13;57;28 - 00;14;02;04 Michele Williams So they go straight to the place that they need to treat versus going out into the. 00;14;02;08 - 00;14;03;23 Morteza Rasoulianboroujeni Exactly. That's the. 00;14;03;25 - 00;14;04;11 Michele Williams Places. 00;14;04;11 - 00;14;30;06 Morteza Rasoulianboroujeni That's the goal. Yes. Thinking about oncology drugs and chemo, a lot of them are hydrophobic. And students who have, who have tech, who are taking, pharmacokinetic course or they know that they distribute all over the body. So when this drug, which is super toxic, is all over the body, it kills all the healthy cells as well as is killing cancer cells. 00;14;30;06 - 00;14;52;08 Morteza Rasoulianboroujeni It's not it has some selectivity mechanisms associated with it, but it's not super selective to what cancer cells. And that's what why you see these side effects. So for patients who are treated with chemotherapy, what we're trying to do is that to encapsulate this in a nanoparticle, and sometimes we add a targeting ligand on the surface of these nanoparticle. 00;14;52;14 - 00;15;14;21 Morteza Rasoulianboroujeni That targeting moiety targeting agent can attach to cancer cells and or cancer tissue more efficiently that it can attach to healthy tissue. So we expect that after injecting, we see more nanoparticles in cancer tissue and no less or no nanoparticle in other tissues. And that way we improve efficacy and we reduce toxicity. 00;15;14;25 - 00;15;23;22 Michele Williams That's amazing. Yeah. So if a student is interested in working with you on your research, what do they need to do? Kind did just. 00;15;23;22 - 00;15;24;19 Morteza Rasoulianboroujeni Reach out to me. 00;15;24;19 - 00;15;25;23 Michele Williams And they can email. 00;15;25;23 - 00;15;48;02 Morteza Rasoulianboroujeni Me. Yes, definitely. I'm very open to kind of very direct communication. And that's what we're doing right now. ... And that, that that's what happened. The current students we have in the lab, they reach out, reach out to me directly, and they express interest in my research. I talk to them, in, in several meetings, and I even present my research in the PowerPoints that I have. 00;15;48;02 - 00;16;25;28 Morteza Rasoulianboroujeni So they have an idea. They know I work on nanomedicine, but they may not be familiar with the details of what I'm doing. So I introduce all those details, first and then if they, still express the interest, I'll share with them several papers to read. And if they continue being interested, then I ask them to sign up for a research elective, for example, if that helps them to also manage their coursework and and credit, for research, and if even if they are interested in to kind of do it beyond just research electives, I'm very open to that and I'll be very happy to work with them. 00;16;26;00 - 00;16;27;16 Michele Williams That's great. Yeah, yeah, yeah. 00;16;27;20 - 00;16;33;07 Stephen Woodward What kind of tools in your lab do you use to manipulate these nanoparticles? Yeah. 00;16;33;07 - 00;17;01;20 Morteza Rasoulianboroujeni So these nanoparticles are made by, by many different ways. But what we try to do to use principles of just mixing different agents, including organic solvent with aqueous, solvent. I can give you an example. You have seen have you ever added oil to water? For sure. You've done what happens? Like if you mix it so like harsh it becomes small. 00;17;01;20 - 00;17;03;08 Michele Williams Droplets little pellets. 00;17;03;08 - 00;17;25;21 Morteza Rasoulianboroujeni Yeah. So let let let's say we do this. We have a polymer which is a piece of plastic but it's biodegradable inside the body. And we dissolve it in a solvent which is hydrophobic, meaning that it doesn't like to mix with water like oil. Right. And we we choose the solvent to be very volatile, meaning that it evaporates very fast. 00;17;25;23 - 00;17;53;11 Morteza Rasoulianboroujeni It leaves that whatever you have, like the beach or the glass, container that you have. So if we put the polymer and the drug in that organic solvent oil, and we add it to water and we mix it harsh, and while we're mixing, we allow the organic solvent to leave the container because it's volatile. What happens is that the particles solidify and while they're solidify, they encapsulate the drug in them. 00;17;53;14 - 00;17;58;22 Morteza Rasoulianboroujeni And then we separate them. And these nanoparticles now can be used for like injection. 00;17;58;27 - 00;18;01;02 Michele Williams And so they're very, very tiny. 00;18;01;02 - 00;18;29;28 Morteza Rasoulianboroujeni Yeah. They're very tiny nano size like tat. If you let me think about it, how I can, you know, give you an A scale so they 10 to -7m, which is like if you put together 1 million of them, right? 1 million of these particles, it's going to be, ten centimeters or like two, three inches. 00;18;30;00 - 00;18;30;19 Michele Williams Oh, wow. 00;18;30;21 - 00;18;31;17 Morteza Rasoulianboroujeni So that's. 00;18;31;17 - 00;18;31;29 Michele Williams A little. 00;18;32;06 - 00;18;48;19 Morteza Rasoulianboroujeni Million of them. Yeah. You put next to each other. So, these nanoparticles should be and that should be the case because when we inject them the blood, if they're large, they lead to very adverse reactions, like the body recognizes them as foreign. 00;18;48;21 - 00;18;52;19 Michele Williams You can't have them in your tissue or in your blood vessels if it's too big. 00;18;52;19 - 00;19;00;07 Morteza Rasoulianboroujeni





